GluSense

Company Overview

Snapshot

Founded in April 2007, GluSense operated with 1–10 employees and raised a total of $7 million across three funding rounds from three investors. The company received a significant grant in February 2017.

Business overview

GluSense is a Health Tech & Life Sciences company focused on developing medical devices for diabetes management. Its core product, Glyde CGM, is a miniature, implantable continuous glucose sensor designed to transmit glucose values to an external unit or smartphone for over a year. This technology aims to improve the quality of life for diabetic patients by providing continuous monitoring. The company operates within the digital healthcare, medical devices, and patient remote monitoring sectors, targeting both B2B and B2B2C markets in geomarkets such as China and the United States.

Strategic signal

In February 2017, GluSense received a grant, signaling continued support for its innovative implantable glucose sensor technology. This funding underscored the potential of its Glyde CGM device to address critical needs in diabetes management, validating its development trajectory and market relevance.

Company Intelligence Q&A

What is GluSense's primary product?

GluSense's primary product is Glyde CGM, a miniature, implantable continuous glucose sensor designed for long-term glucose monitoring and data transmission to external devices.

When was GluSense founded?

GluSense was founded in April 2007.

What is GluSense's operational status?

GluSense is currently non-active, having ceased operations in February 2021.

What was a key funding event for GluSense?

In February 2017, GluSense received a $2 million grant from JDRF to support the development of its injectable glucose sensor.